Maryam Sorkhou1,2, Rachel H Bedder3, Tony P George1,2,4. 1. Addictions Division, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, ON, Canada. 2. Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada. 3. Department of Psychology, Ryerson University, Toronto, ON, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Abstract
Background: Cannabis is known to have a broad range of effects on behavior, including experiencing a "high" and tranquility/relaxation. However, there are several adverse behavioral sequalae that can arise from cannabis use, depending on frequency of use, potency (e.g., THC content), age of onset, and cumulative exposure. This systematic review examined evidence for cannabis-related adverse behavioral sequalae in otherwise healthy human subjects. Methods: Following PRISMA guidelines, we conducted a systematic review of cross-sectional and longitudinal studies from 1990 to 2020 that identified cannabis-related adverse behavioral outcomes in subjects without psychiatric and medical co-morbidities from PubMed and PsychInfo searches. Key search terms included "cannabis" OR "tetrahydrocannabinol" OR "cannabidiol" OR "marijuana" AND "anxiety" OR "depression" OR "psychosis" OR "schizophrenia" "OR "IQ" OR "memory" OR "attention" OR "impulsivity" OR "cognition" OR "education" OR "occupation". Results: Our search detected a total of 2,870 studies, from which we extracted 124 relevant studies from the literature on cannabis effects in the non-clinical population. Effects of cannabis on several behavioral sequelae including cognition, motivation, impulsivity, mood, anxiety, psychosis intelligence, and psychosocial functioning were identified. The preponderance of the evidence suggests that frequency of cannabis use, THC (but not CBD) content, age of onset, and cumulative cannabis exposure can all contribute to these adverse outcomes in individuals without a pre-existing medical condition or psychiatric disorder. The strongest evidence for the negative effects of cannabis are for psychosis and psychosocial functioning. Conclusions: Although more research is needed to determine risk factors for development of adverse behavioral sequelae of cannabis use, these findings underline the importance of understanding vulnerability to the adverse effects of cannabis, which has implications for prevention and treatment of problematic cannabis use.
Background: Cannabis is known to have a broad range of effects on behavior, including experiencing a "high" and tranquility/relaxation. However, there are several adverse behavioral sequalae that can arise from cannabis use, depending on frequency of use, potency (e.g., THC content), age of onset, and cumulative exposure. This systematic review examined evidence for cannabis-related adverse behavioral sequalae in otherwise healthy human subjects. Methods: Following PRISMA guidelines, we conducted a systematic review of cross-sectional and longitudinal studies from 1990 to 2020 that identified cannabis-related adverse behavioral outcomes in subjects without psychiatric and medical co-morbidities from PubMed and PsychInfo searches. Key search terms included "cannabis" OR "tetrahydrocannabinol" OR "cannabidiol" OR "marijuana" AND "anxiety" OR "depression" OR "psychosis" OR "schizophrenia" "OR "IQ" OR "memory" OR "attention" OR "impulsivity" OR "cognition" OR "education" OR "occupation". Results: Our search detected a total of 2,870 studies, from which we extracted 124 relevant studies from the literature on cannabis effects in the non-clinical population. Effects of cannabis on several behavioral sequelae including cognition, motivation, impulsivity, mood, anxiety, psychosis intelligence, and psychosocial functioning were identified. The preponderance of the evidence suggests that frequency of cannabis use, THC (but not CBD) content, age of onset, and cumulative cannabis exposure can all contribute to these adverse outcomes in individuals without a pre-existing medical condition or psychiatric disorder. The strongest evidence for the negative effects of cannabis are for psychosis and psychosocial functioning. Conclusions: Although more research is needed to determine risk factors for development of adverse behavioral sequelae of cannabis use, these findings underline the importance of understanding vulnerability to the adverse effects of cannabis, which has implications for prevention and treatment of problematic cannabis use.
Authors: M F H Griffith-Lendering; S C J Huijbregts; A Mooijaart; W A M Vollebergh; H Swaab Journal: Drug Alcohol Depend Date: 2011-01-03 Impact factor: 4.492
Authors: Rachel A Rabin; Mera S Barr; Michelle S Goodman; Yarissa Herman; Konstantine K Zakzanis; Stephen J Kish; Michael Kiang; Gary Remington; Tony P George Journal: Neuropsychopharmacology Date: 2017-04-26 Impact factor: 7.853
Authors: Claire Mokrysz; Natacha D C Shaban; Tom P Freeman; Will Lawn; Rebecca A Pope; Chandni Hindocha; Abigail Freeman; Matthew B Wall; Michael A P Bloomfield; Celia J A Morgan; David J Nutt; H Valerie Curran Journal: Psychol Med Date: 2020-04-28 Impact factor: 7.723
Authors: Andrea H Weinberger; Jiaqi Zhu; Joun Lee; Elle Anastasiou; Jan Copeland; Renee D Goodwin Journal: Drug Alcohol Depend Date: 2020-02-06 Impact factor: 4.492
Authors: Nadia Solowij; Katy A Jones; Megan E Rozman; Sasha M Davis; Joseph Ciarrochi; Patrick C L Heaven; Dan I Lubman; Murat Yücel Journal: Psychopharmacology (Berl) Date: 2011-02-17 Impact factor: 4.530
Authors: Edison Manrique-Garcia; Stanley Zammit; Christina Dalman; Tomas Hemmingsson; Peter Allebeck Journal: BMC Psychiatry Date: 2012-08-16 Impact factor: 3.630
Authors: Karolina Kozak; Philip H Smith; Darby J E Lowe; Andrea H Weinberger; Ziva D Cooper; Rachel A Rabin; Tony P George Journal: Am J Drug Alcohol Abuse Date: 2021-07-19 Impact factor: 3.912